GLP-1 Drugs Explained — What Ozempic, Wegovy, and Zepbound Actually Do
GLP-1 medications have gone from a niche diabetes treatment to one of the most talked-about drug categories in modern medicine, with roughly 1 in 8 American adults now taking one. This guide explains how these drugs work, what separates Ozempic from Wegovy from Zepbound, what the real risks and costs are, and what current research actually shows.
GLP-1 receptor agonists are injectable (and now oral) medications originally developed for type 2 diabetes. Source: FDA prescribing information
GLP-1 Drugs by the Numbers
Few medication categories have grown this fast. What started as a diabetes treatment is now one of the most significant shifts in obesity medicine in decades.
How GLP-1 Drugs Actually Work
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating. It signals your pancreas to release insulin, slows down how quickly your stomach empties, and tells your brain that you're full. GLP-1 receptor agonist medications mimic and amplify this hormone's natural effects.
Slower Digestion
Food moves more slowly from your stomach to your intestines, which helps control post-meal blood sugar spikes and extends feelings of fullness.
Appetite Reduction
The medication acts on appetite centers in the brain, meaningfully reducing hunger signals and food cravings for most users.
Improved Insulin Response
Stimulates insulin release only when blood sugar is actually elevated, which is why these drugs don't typically cause low blood sugar on their own.
Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound
The naming is genuinely confusing because the same active ingredients are sold under different brand names depending on the approved use.
| Brand Name | Active Ingredient | FDA-Approved For | Notes |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | Also reduces cardiovascular risk in people with heart disease; not FDA-approved specifically for weight loss |
| Wegovy | Semaglutide (higher dose) | Weight loss / obesity | Same drug as Ozempic at a higher maximum dose; approved for adults and some adolescents 12+ |
| Rybelsus | Oral semaglutide | Type 2 diabetes | First oral GLP-1 formulation; requires taking on an empty stomach with minimal water |
| Mounjaro | Tirzepatide | Type 2 diabetes | Dual GLP-1/GIP mechanism, generally shows stronger average weight loss results than semaglutide |
| Zepbound | Tirzepatide (weight-loss dose) | Weight loss / obesity | Same drug as Mounjaro; currently considered among the most effective approved obesity treatments |
Side Effects and Real Risks
GLP-1 drugs are generally well-tolerated, but they are not risk-free, and side effects are common enough that patients should know what to expect before starting.
Common and Serious Side Effects
- Very common: nausea, vomiting, diarrhea, and constipation, especially when starting or increasing the dose
- Common: fatigue, heartburn, and abdominal discomfort
- Less common but serious: gallbladder problems, pancreatitis, and in rare cases, changes in vision for people with diabetic retinopathy
- Muscle loss: a meaningful portion of weight lost on these drugs can be lean muscle mass, not just fat — resistance training and adequate protein intake are recommended alongside treatment
- These medications carry a boxed warning regarding thyroid C-cell tumors seen in rodent studies; people with a personal or family history of certain thyroid cancers should not take them
Cost and Access in 2026
Pricing has shifted substantially this year. Following negotiated federal pricing agreements, Ozempic, Wegovy, Mounjaro, and Zepbound became available at $245 per month through the TrumpRx program — roughly half of prior list prices. An oral version of Wegovy also launched, starting around $149 per month for cash-pay patients, removing the injection barrier for some patients. Insurance coverage varies significantly; Medicaid GLP-1 prescriptions have grown to roughly 8.4 million as of 2026, while private coverage remains inconsistent depending on employer and plan.
Key Takeaways
- GLP-1 drugs mimic a natural gut hormone to reduce appetite, slow digestion, and improve blood sugar control
- About 1 in 8 US adults currently take a GLP-1 medication as of mid-2026
- Tirzepatide-based drugs (Mounjaro, Zepbound) generally produce greater average weight loss than semaglutide-based drugs (Ozempic, Wegovy)
- Nausea and GI side effects are common; serious risks like pancreatitis are rare but real
- New federal pricing agreements have roughly halved the monthly cost for many patients in 2026
- These are prescription medications that require medical supervision — not something to self-administer or obtain outside a licensed provider
More Health Guides, Written Clearly
Browse our full library of medically reviewed articles on diabetes, heart health, and weight management — all in plain, easy-to-understand language.
Explore All Health ArticlesSources and References
- Gallup National Health and Well-Being Index — GLP-1 Usage Reaches New High, 2026
- Forbes Health — GLP-1 Statistics & Trends 2026, citing WHO, CDC, and FDA data
- Stanford Medicine — GLP-1s 101: What the Science Says, 2026
- GoodRx — Comparing Ozempic, Wegovy, and Other GLP-1 Drugs
- Westchester Medical Center Health Network — How GLP-1s Actually Work